| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785756 | Cancer Treatment and Research Communications | 2018 | 5 Pages |
Abstract
Administration of D1 pegfilgrastim is cost-effective in women with ovarian cancer who are treated with intermediate risk chemotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Caroline C. Billingsley, David E. Cohn, Aleia K. Crim, Quan Li, David M. O'Malley, Laura J. Havrilesky,